Voyageur Pharmaceuticals Ltd. Toronto S.E.

VM

CA92916K1057

Pharmaceuticals

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+7.14%	-.--%

Jun. 11	Voyageur Pharmaceuticals Ltd. and Rain Cage Carbon Inc. Announce Follow Up on the First Commercial Creation of V@C60 Endohedral Fullerene	CI
May. 28	Voyageur Pharmaceuticals Ltd Secures USD 1.9 Million Sales Contract for SmoothXTM 2% Barium Contrast	CI

Voyageur Pharmaceuticals Ltd. Announces the Retirement of Charles Littlejohn from the Board with A Timeline of April, 2021

January 18, 2021 at 09:35 am EST

Voyageur Pharmaceuticals Ltd. announced that Mr. Charles Littlejohn, a director of the Company, has advised the board of directors that he intends to retire from the board with a timeline of April, 2021.

Latest news about Voyageur Pharmaceuticals Ltd.

Voyageur Pharmaceuticals Ltd. and Rain Cage Carbon Inc. Announce Follow Up on the First Commercial Creation of V@C60 Endohedral Fullerene	Jun. 11	CI
Voyageur Pharmaceuticals Ltd Secures USD 1.9 Million Sales Contract for SmoothXTM 2% Barium Contrast	May. 28	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 29, 2024	Apr. 26	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2023	Mar. 26	CI
Voyageur Pharmaceuticals Ltd. Announces A Significant Advancement in Its Partnership with Rain Cage Carbon Inc	Mar. 13	CI
Voyageur Pharmaceuticals Ltd. and Applied Pharmaceutical Innovation Sign Master Services Agreement	Mar. 04	CI
Voyageur Pharmaceuticals Ltd. announced that it has received CAD 0.4885 million in funding	Feb. 29	CI
Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 0.8 million in funding	Jan. 15	CI
Voyageur Pharmaceuticals Ltd. Announces the Formalization of A Pivotal Sales and Distribution Alliance	Dec. 14	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	23-10-30	CI
Voyageur Pharmaceuticals Ltd. Announces Board Changes	23-08-01	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-31	CI
Voyageur Pharmaceuticals Ltd. Announces the Release of the White Paper	23-06-12	CI
Voyageur Pharmaceuticals Ltd. Advances with Environmental Field Work At Frances Creek Project Site for Notice of Work & Quarry Permitting	23-05-31	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-04-28	CI
Voyageur Pharmaceuticals Ltd. Completes Comparative Studies of Its SmoothX® Contrast Media Confirming Product Superiority	23-04-06	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2022	23-03-30	CI
Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Voyageur Pharmaceuticals Ltd. announced that it has received CAD 1.199949 million in funding	23-01-19	CI
Voyageur Pharmaceuticals Ltd. Announces Canadian Launch of Smoothx Barium Contrast Media & Financing	22-12-08	CI
Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 0.65 million in funding	22-12-07	CI
Voyageur Pharmaceuticals Ltd. Completes Medical Imaging CT Contrast Agent Production Testing and Begins Production Scale-Up of SmoothX	22-11-28	CI
Voyageur Pharmaceuticals Ltd. Completes Design of Carbon Neutral Pharmaceutical Facility on Alberta	22-11-01	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-10-31	CI
Voyageur Pharmaceuticals’ MOU with Rain Cage Carbon to Develop Fullerene-Based Medical Contrast Agents from Carbon Capture of Hydrocarbon Exhaust Systems	22-10-26	CI

Chart Voyageur Pharmaceuticals Ltd.

Duration

Period

More charts

Company Profile

Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada and the state of Utah, United States. Its properties include Jubilee Mountain, Falcon and Paradox Basin. It owns a 100% interest in two barium sulphate (barite) projects, including the Frances Creek and Pedley Mountain property. It holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah, United States. It owns a 100% interest in two battery mineral projects that is focused on copper/zinc development. Its pipeline products include SmoothX 2.0%, MultiX Thick, MultiX Thin, HDX, LDX, VY-101 and VY-103.

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B
PFIZER, INC.	+0.45%	164B

Other Pharmaceuticals

Voyageur Pharmaceuticals Ltd. Toronto S.E.

Equities

VM

CA92916K1057

Pharmaceuticals

Voyageur Pharmaceuticals Ltd. Announces the Retirement of Charles Littlejohn from the Board with A Timeline of April, 2021

Latest news about Voyageur Pharmaceuticals Ltd.

Chart Voyageur Pharmaceuticals Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals